Viz.ai AI-Powered Solution Identifies Hypertrophic Cardiomyopathy Earlier, Enhancing Clinical Care Viz.ai, a leading company in AI-powered disease detection and intelligent care coordination, has announced compelling new clinical data demonstrating the…
Coya Therapeutics Advances Treg-Derived Exosome Program Coya Therapeutics, Inc. (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function, has provided…
Global Pharma Leader Adopts ValGenesis iClean for Digital Cleaning Validation ValGenesis, Inc., a global leader in digital validation lifecycle management solutions, has announced a significant milestone in its collaboration with…
Epicrispr Biotech Raises $68M for FSHD Epigenetic Therapy Trial Epicrispr Biotechnologies, a pioneering biotechnology company dedicated to developing curative therapies, has announced the successful first close of its Series B…
RenovoRx TAMP™ Pre-Clinical Results to Be Awarded at SIR 2025 RenovoRx, Inc. (“RenovoRx” or the “Company”), a pioneering life sciences company dedicated to advancing targeted oncology therapies, is pleased to…
Merck Licenses HRS-5346 for Cardiovascular Disease from Hengrui Merck, known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a leading global…
Xcell Biosciences Partners with Planet Innovation and Royal Perth Hospital to Advance Cell Therapy Manufacturing Xcell Biosciences Australia Pty Ltd (Xcellbio), a subsidiary of the San Francisco-based biotechnology company specializing…
FDA Approves Blujepa (Gepotidacin) for uUTIs in Adults & Teens GSK plc has announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of…
Veracyte’s Whole-Genome Sequencing-Based MRD Test Shows High Accuracy for Muscle-Invasive Bladder Cancer Detection Veracyte, Inc., a leader in cancer diagnostics, has announced groundbreaking new data demonstrating the accuracy and effectiveness…
$13.5B Oligonucleotide Synthesis Market Outlook to 2035: Pharma & Biopharma Dominate The global oligonucleotide synthesis market is poised for significant growth, expanding from USD 4.8 billion in the current year…
Dr. Mike Graham Named Head of R&D at Bayer Crop Science Bayer has officially announced that Dr. Mike Graham will assume the role of Head of Research & Development (R&D)…
Quince Therapeutics Shares Business Update & 2024 Financial Results Quince Therapeutics, Inc., a late-stage biotechnology company focused on leveraging a patient’s own biology to treat rare diseases, has provided an…